Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination

ABSTRACT

Purpose

To report a relapse of Vogt-Koyanagi-Harada (VKH) disease in a patient after COVID-19 vaccination.

Case Report

A VKH disease patient, well controlled on azathioprine therapy, presented a uveitis relapse eleven days after the first vaccination for COVID-19. She received an induction high-dose intravenous corticosteroid therapy, followed by oral therapy, which led to a complete recovery from the uveitis in two weeks. No relapses occurred in the following five months of follow-up. Despite high-dose corticosteroid therapy and azathioprine, and one dose only of vaccination, the patient resulted positive for anti-RBD spike COV19 antibody.

Conclusion

Relapse of VKH disease can occur after COVID-19 vaccination, despite an appropriate immunosuppressive therapy is ongoing. It responds to the classic therapy for VKH, and a serological response to an incomplete COVID-19 vaccination can also be found

KEYWORDS:

• Vogt-Koyanagi-Harada
• uveitis
• COVID19
• vaccination
• anti-spike antibody

Disclosure statement

No potential conflict of interest was reported by the author(s).

Informed consent

The patient has signed an informed consent for publication of the case in anonymous form

Additional information

Funding

The author(s) reported that there is no funding associated with the work featured in this article.